Richard A. Larson to Drug Resistance, Multiple
This is a "connection" page, showing publications Richard A. Larson has written about Drug Resistance, Multiple.
Connection Strength
0.467
-
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 2003 Mar; 17(3):488-91.
Score: 0.220
-
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15; 100(4):1224-32.
Score: 0.212
-
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9.
Score: 0.020
-
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
Score: 0.015